Raymond James Financial Inc. Buys 147,492 Shares of Haemonetics Corporation $HAE

Key Points

• Raymond James Financial Inc. has increased its stake in Haemonetics Corporation by 60.6%, acquiring an additional 147,492 shares, bringing their total ownership to approximately 390,856 shares valued at around $24.8 million.
• Haemonetics reported a quarterly earnings per share (EPS) of $1.10, exceeding analyst expectations, though its revenue was down 4.4% year-over-year.
• Current analyst ratings for Haemonetics indicate a consensus of Moderate Buy with an average target price of $85.18, amidst varying opinions on its stock performance.

Raymond James Financial Inc. raised its stake in Haemonetics Corporation (NYSE:HAE - Free Report) by 60.6% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 390,856 shares of the medical instruments supplier's stock after purchasing an additional 147,492 shares during the period. Raymond James Financial Inc. owned approximately 0.78% of Haemonetics worth $24,839,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. TD Waterhouse Canada Inc. acquired a new position in shares of Haemonetics in the 4th quarter valued at $25,000. University of Texas Texas AM Investment Management Co. acquired a new position in shares of Haemonetics in the 1st quarter valued at $65,000. KBC Group NV raised its stake in shares of Haemonetics by 19.9% in the 1st quarter. KBC Group NV now owns 2,417 shares of the medical instruments supplier's stock valued at $154,000 after buying an additional 401 shares in the last quarter. Vise Technologies Inc. raised its stake in shares of Haemonetics by 8.7% in the 4th quarter. Vise Technologies Inc. now owns 2,825 shares of the medical instruments supplier's stock valued at $221,000 after buying an additional 225 shares in the last quarter. Finally, CWC Advisors LLC. raised its stake in shares of Haemonetics by 7.4% in the 4th quarter. CWC Advisors LLC. now owns 3,083 shares of the medical instruments supplier's stock valued at $241,000 after buying an additional 212 shares in the last quarter. 99.67% of the stock is owned by institutional investors.

Haemonetics Stock Performance

HAE opened at $55.3020 on Tuesday. Haemonetics Corporation has a 52-week low of $50.68 and a 52-week high of $94.99. The company has a quick ratio of 1.04, a current ratio of 1.72 and a debt-to-equity ratio of 1.04. The company has a market cap of $2.66 billion, a P/E ratio of 16.91, a price-to-earnings-growth ratio of 1.04 and a beta of 0.40. The firm's 50-day moving average price is $69.21 and its 200-day moving average price is $66.28.

Haemonetics (NYSE:HAE - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.10 earnings per share for the quarter, topping the consensus estimate of $1.01 by $0.09. Haemonetics had a net margin of 12.14% and a return on equity of 26.64%. The company had revenue of $321.39 million for the quarter, compared to the consensus estimate of $305.12 million. During the same quarter in the prior year, the company earned $1.02 EPS. Haemonetics's quarterly revenue was down 4.4% on a year-over-year basis. Haemonetics has set its FY 2026 guidance at 4.700-5.00 EPS. As a group, equities analysts anticipate that Haemonetics Corporation will post 4.55 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the stock. Robert W. Baird assumed coverage on shares of Haemonetics in a research report on Thursday, June 26th. They set an "outperform" rating and a $87.00 target price for the company. JMP Securities reiterated a "market outperform" rating and set a $100.00 target price on shares of Haemonetics in a research report on Tuesday, May 20th. JPMorgan Chase & Co. reiterated a "neutral" rating and set a $62.00 target price (down previously from $85.00) on shares of Haemonetics in a research report on Friday, August 8th. Raymond James Financial cut shares of Haemonetics from a "strong-buy" rating to an "outperform" rating and dropped their target price for the stock from $105.00 to $78.00 in a research report on Monday, August 11th. Finally, Wall Street Zen cut shares of Haemonetics from a "buy" rating to a "hold" rating in a research report on Tuesday, May 13th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $85.18.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.

Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Corporation (NYSE:HAE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.